ENGN Stock Forecast: enGene Therapeutics, Inc. Price Predictions for 2026-2027
The 9 Wall Street analysts covering enGene Therapeutics, Inc. hold a median 12-month price target of $4 — +127.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 21 of 100 as at 18 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores enGene Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (60): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ENGN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ENGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +127.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Leerink Partners | Upgrade | Outperform | $5.00 |
| 12 Nov 2026 | Piper Sandler | Upgrade | Overweight | $4.00 |
| 12 Nov 2026 | Wells Fargo | Upgrade | Overweight | $2.00 → $6.00 |
| 9 Sept 2026 | Citizens | Reiterates | Market Perform | — |
| 8 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $4.00 |
| 18 June 2026 | Morgan Stanley | Downgrade | Underweight | — |
| 16 June 2026 | HC Wainwright & Co. | Maintains | Buy | $6.00 → $4.00 |
| 14 May 2026 | UBS | Maintains | Neutral | — |
| 8 May 2026 | Citizens | Downgrade | Market Perform | — |
| 8 May 2026 | Guggenheim | Downgrade | Neutral | — |
| 8 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 May 2026 | Piper Sandler | Downgrade | Neutral | — |
| 8 May 2026 | Wells Fargo | Downgrade | Equal-Weight | — |
| 13 Apr 2026 | WBB Securities | Initiates | Buy | — |
| 11 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 9 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 12 Nov 2025 | Morgan Stanley | Maintains | Overweight | — |
| 12 Nov 2025 | Oppenheimer | Reiterates | Outperform | — |
| 12 Nov 2025 | UBS | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ENGN.
This page is one stock. Monday covers all of them.
ENGN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ENGN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, enGene Therapeutics, Inc. returned −74.0% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ENGN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.5×
- EV / EBITDA
- —
Cheaper than 86% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −60.5%
- Return on assets
- −32.0%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
enGene Therapeutics, Inc. has a market value of $117.9M.
Revenue in the twelve months to 31 July 2026: $0.0.
Net income over the same four quarters: −$130.4M.
Free cash flow in the twelve months to 31 July 2026: −$104.0M.
enGene Therapeutics, Inc. employs 81 people.
Data provided by Twelve Data
ENGN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ENGN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own enGene Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ENGN
What is the ENGN stock price forecast for 2026-2027?
The 9 Wall Street analysts covering enGene Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $2 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ENGN stock a buy right now?
Of the 9 analysts covering enGene Therapeutics, Inc., 6 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks enGene Therapeutics, Inc. 21 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ENGN?
As at 18 Nov 2026, enGene Therapeutics, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (60 of 100).
Will ENGN stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts implies +127.3% from the last close, and Ticker Nerd's factor model ranks enGene Therapeutics, Inc. 21 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ENGN stock forecast for 2030?
No analyst covering enGene Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $6 over the next 12 months.
How has ENGN stock performed over the past year?
enGene Therapeutics, Inc. returned -74.0% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does enGene Therapeutics, Inc. do?
enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for diseases with significant unmet medical needs. The company’s work centers on its proprietary DDX delivery platform, which is designed to deliver DNA and RNA-based therapies directly to mucosal tissues and other target organs.
About enGene Therapeutics, Inc.
enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for diseases with significant unmet medical needs. The company’s work centers on its proprietary DDX delivery platform, which is designed to deliver DNA and RNA-based therapies directly to mucosal tissues and other target organs. Its lead product candidate, detalimogene voraplasmid, is being developed as a monotherapy for non-muscle invasive bladder cancer, including difficult-to-treat high-risk cases. enGene Therapeutics Inc. also advances a broader pipeline of gene therapy programs aimed at localized treatment delivery in oncology and other therapeutic areas. Based in Montreal, Canada, the company plays a specialized role in the biotechnology market by pursuing tissue-targeted genetic therapies that seek to address complex diseases through precision delivery approaches.
CEO Mr. Ronald H. W. Cooper · 81 employees · Canada · https://www.engene.com